ChagasLAMP-2

Duration

01/01/2026 - 31/12/2027

Coordinator

Julio Alonso Padilla

Funded by

Global Health Innovative Technology Fund (GHIT Fund)

Chagas disease, caused by the parasite Trypanosoma cruzi, affects more than 6.5 million people in Latin America and over 0.5 million elsewhere. While vector-borne transmission is increasingly being brought under control, mother-to-child transmission remains a public health challenge. The two available drugs (benznidazole and nifurtimox) are highly effective and well tolerated by newborns, making early diagnosis essential to ensure timely access to treatment.

However, the current algorithm for detecting congenital infection takes months, requires multiple tests and has limited sensitivity. The main goal of G2025-121 is to register the T. cruzi-LAMP assay as a product for the detection of congenital Chagas disease. LAMP is a near point-of-care molecular tool that matches standard PCR in sensitivity and specificity, while being simpler to perform, offering a faster turnaround time and having a lower expected cost. The project aims to license T. cruzi-LAMP in Argentina and Bolivia, with ANMAT and AGEMED, respectively.

Total Funding

¥ 93,142,925

Funded by Global Health Innovative Technology Fund (GHIT Fund)